[1]
|
N.Sultana, M.S. Arayane, S.S Ali and S. Sajid, “Simultaneous determination of olmesartan medoxomil and irbesartan and hydrochlorothiazide in pharmaceutical formulations and human serum using high performance liquid chromatography” Chinese Journal of Chromatography, Vol. 26, No. 5, 2008, pp. 544-549.
|
[2]
|
B. Lisiane, R. C. Rochele, D. L. Carolina B. M. Ana and F.E. Pedro, “Stability-Indicating LC Determination of a New Antihypertensive, Olmesartan Medoxomil in Tablets” Chromatographia, Vol. 68, 2008, pp. 991-996.
|
[3]
|
P. D. Bari and A. Rote, “RP-LC and HPTLC Methods for the Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Combined Tablet Dosage Forms,” Chromatographia, Vol. 69, 2009, pp. 1469-1472.
|
[4]
|
Chrysant and G. Steven, “Amlodipine besylate/olmesar- tan medoximil fixed combination for the treatment of hypertension,” Expert Review of Cardiovascular Therapy, Vol. 7, No. 8, 2009, pp. 887-895.
|
[5]
|
D. Liua, P. Hu, N. Matsushima, X. Lia, L. Lia and Ji, “Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry”, Journal of Chromatography B, Vol. 856, No.1-2, 2007, pp. 190-197.
|
[6]
|
B. Yuan, X. Wang, F. Zhang, J. Jia and F. Tang, “Simultaneous Determination of Ramipril and Its Active Metabolite Ramiprilat in Human Plasma by LC–MS–MS,” Chromatographia, Vol. 68, No. 7-8, pp. 533-539.
|
[7]
|
Persson and B. Arne, “Interference from a glucuronide metabolite in the determination of ramipril and ramiprilat in human plasma and urine by gas chromatography–mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 40, No.3, 2006, pp.794-797.
|
[8]
|
L Xiao-yang, “High-performance liquid chromatography?mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: Application to a pharmacokinetic study in the Chinese volunteers,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 40, No. 2, 2006, pp. 478-483.
|
[9]
|
Z. Zhimeng, “Liquid chromatography-mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma,” Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, Vol. 779, No. 2, 2002, pp. 297-306.
|
[10]
|
G. E. Linda, “Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects,” Clinical Therapeutics, Vol. 28, No. 3, 2006, pp.373.
|
[11]
|
Z. Zhu, A. Vachareau and L. Neirinck, “Liquid chromatography–mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma” Journal of Chromatography B, Vol. 779, No. 2, 2002, pp. 297-306.
|
[12]
|
V. P. Chintan, P.K Amit, D.C. Anandi and T.P Kalpesh, “Validated Absorption Factor Spectrophotometric and Reversed-Phase High-Performance Liquid Chromatographic Methods for the Determination of Ramipril and Olmesartan Medoxomil in Pharmaceutical Formulations,” Eurasian Journal of Analytical Chemistry, Vol. 2, No. 3, 2007, pp. 159-171.
|